Common Contracts
24 similar null contracts by BOSTON OMAHA Corp, Dynavax Technologies Corp, Merrimack Pharmaceuticals Inc, others
SYNDAX PHARMACEUTICALS, INC. common Stock (par value $0.0001 per share) SALES AGREEMENTSyndax Pharmaceuticals Inc • May 26th, 2023 • Pharmaceutical preparations • New York
Syndax Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
2 - contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or 462(b) of the Securities Act, or...Anaptysbio, Inc • November 8th, 2022 • Pharmaceutical preparations • New York
unity biotechnology, inc. $50,000,000 shares of common stock SALES AGREEMENTUnity Biotechnology, Inc. • March 15th, 2022 • Pharmaceutical preparations • New York
Unity Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ALPINE IMMUNE SCIENCES, INC. $75,000,000 OF SHARES OF COMMON STOCK SALES AGREEMENTAlpine Immune Sciences, Inc. • July 2nd, 2021 • Pharmaceutical preparations • New York
Alpine Immune Sciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ARCUTIS BIOTHERAPEUTICS, INC. $100,000,000 SHARES OF COMMON STOCK PAR VALUE $0.0001 PER SHARE SALES AGREEMENTArcutis Biotherapeutics, Inc. • May 6th, 2021 • Pharmaceutical preparations • New York
Arcutis Biotherapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
Albireo pharma, Inc. Common Stock (par value $0.01 per share) SALES AGREEMENTAlbireo Pharma, Inc. • February 25th, 2021 • Pharmaceutical preparations • New York
Albireo Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
DERMTECH, INC. $50,000,000 SALES AGREEMENTDermTech, Inc. • November 10th, 2020 • Services-medical laboratories • New York
DermTech, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ADAMAS PHARMACEUTICALS, INC. $50,000,000 COMMON STOCK SALES AGREEMENTAdamas Pharmaceuticals Inc • November 7th, 2019 • Pharmaceutical preparations • New York
Adamas Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ALLOGENE THERAPEUTICS, INC. $250,000,000 COMMON STOCK SALES AGREEMENTAllogene Therapeutics, Inc. • November 5th, 2019 • Biological products, (no disgnostic substances) • New York
Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
BOSTON OMAHA CORPORATION $75,000,000 CLASS A COMMON STOCK, PAR VALUE $0.001 PER SHARE SALES AGREEMENTBOSTON OMAHA Corp • August 13th, 2019 • Real estate operators (no developers) & lessors • New York
Boston Omaha Corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
Affimed N.V. $50,000,000 Common Shares SALES AGREEMENTAffimed N.V. • October 22nd, 2018 • Pharmaceutical preparations • New York
50,000,000 AT-THE-MARKET OFFERING PROGRAM SALES AGREEMENTVirnetX Holding Corp • August 31st, 2018 • Patent owners & lessors • New York
VirnetX Holding Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
TONIX PHARMACEUTICALS HOLDING CORP. $9,500,000 COMMON STOCK SALES AGREEMENTTonix Pharmaceuticals Holding Corp. • May 1st, 2018 • Pharmaceutical preparations • New York
Tonix Pharmaceuticals Holding Corp. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
BOSTON OMAHA CORPORATION $50,000,000 CLASS A COMMON STOCK, PAR VALUE $0.001 PER SHARE SALES AGREEMENTBOSTON OMAHA Corp • March 2nd, 2018 • Real estate operators (no developers) & lessors • New York
Boston Omaha Corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ACHAOGEN, INC. $50,000,000 COMMON STOCK SALES AGREEMENTAchaogen Inc • February 27th, 2018 • Pharmaceutical preparations • New York
Achaogen, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
MERRIMACK PHARMACEUTICALS, INC. $40,000,000 of shares of Common Stock, par value $0.01 per share Sales AgreementMerrimack Pharmaceuticals Inc • December 15th, 2017 • Pharmaceutical preparations • New York
Merrimack Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
VIVEVE MEDICAL, INC. $25,000,000 COMMON STOCK SALES AGREEMENTViveve Medical, Inc. • November 8th, 2017 • Electromedical & electrotherapeutic apparatus • New York
CHIMERIX, INC. $75,000,000 COMMON STOCK SALES AGREEMENTChimerix Inc • November 8th, 2017 • Pharmaceutical preparations • New York
25,000,000 COMMON STOCK SALES AGREEMENTOpgen Inc • September 14th, 2016 • Services-medical laboratories • New York
ADURO BIOTECH, INC. $100,000,000 cOMMON STOCK SALES AGREEMENTAduro Biotech, Inc. • May 2nd, 2016 • Pharmaceutical preparations • New York
DYNAVAX TECHNOLOGIES CORPORATIONDynavax Technologies Corp • November 12th, 2015 • Pharmaceutical preparations • New York
Dynavax Technologies Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
THRESHOLD PHARMACEUTICALS, INC. $50,000,000 SALES AGREEMENTThreshold Pharmaceuticals Inc • November 2nd, 2015 • Pharmaceutical preparations • New York
Threshold Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
MERRIMACK PHARMACEUTICALS, INC. $40,000,000 of shares of Common Stock, par value $0.01 per share Sales AgreementMerrimack Pharmaceuticals Inc • July 13th, 2015 • Pharmaceutical preparations • New York
Merrimack Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
DYNAVAX TECHNOLOGIES CORPORATIONDynavax Technologies Corp • November 10th, 2014 • Pharmaceutical preparations • New York
Dynavax Technologies Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
